ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by "Overcoming Resistance In Cancer" (ORIC). The company's mission is to discover and develop novel oncology therapies that address resistance biology to extend and deepen patient responses, with an emphasis on central nervous system (CNS) activity and durable outcomes. Headquartered in South San Francisco, California, with an additional office in San Diego, California, ORIC Pharmaceuticals was established in 2014.

ORIC Pharmaceuticals focuses on developing therapies that target innate, acquired, and bypass resistance mechanisms in cancer. Its pipeline includes several clinical-stage product candidates. Rinzimetostat (ORIC-944) is an allosteric inhibitor of PRC2 via the EED subunit, being developed for prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Enozertinib (ORIC-114) is a brain-penetrant inhibitor designed to selectively target EGFR exon 20, EGFR atypical, and HER2 exon 20 mutations, primarily for non-small cell lung cancer (NSCLC). Additionally, ORIC-533 is an orally bioavailable small molecule inhibitor of CD73, under development for multiple myeloma. The company leverages its expertise in hormone-dependent cancers, precision oncology, and key tumor dependencies.

Led by President and CEO Jacob Chacko, MD, ORIC Pharmaceuticals went public with an IPO in April 2020. Recent notable developments include reporting Phase 1b data for rinzimetostat (ORIC-944) in mCRPC, which demonstrated potential best-in-class efficacy and safety, leading to the selection of a recommended Phase 3 dose (RP3D) for a global registrational trial expected to initiate in the first half of 2026. Initial Phase 1b data for enozertinib (ORIC-114) in EGFR exon 20 mutated NSCLC have also shown systemic and intracranial activity. The company has strengthened its financial position with $125 million in financing in 2024, extending its operational runway into late 2026 or 2027, and has announced collaborations with major pharmaceutical companies like Pfizer, Bayer, and Johnson & Johnson to advance its therapies.